profit from every $100 of sales.
$0$100
Collegium Pharmaceutical
$25.32+1.48% today
-45.4% in 1 year
1-year low $21.531-year high $49.84
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $12.52 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Collegium Pharmaceutical sold, what it kept, and what it did with the cash.
Sales went from $464 million in 2022 to $781 million in 2025, with $62.9 million of profit last year.
SalesProfit
Collegium Pharmaceutical handed back 8% of the cash it generated last year.
Buybacks $25M
Free cash flow 2025$328M
Bought back its own shares$25M
Paid as dividends–
Cash vs. debt$231M vs. $815M
Collegium Pharmaceutical vs. similar companies
Collegium Pharmaceutical grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Collegium Pharmaceutical | 12.5× · Cheap | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Collegium Pharmaceutical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 464 | 567 | 631 | 781 | |
| 209 | 326 | 377 | 463 | |
| 33 | 167 | 167 | 178 | |
| 173 | 308 | 342 | 401 | |
| -25 | 48 | 69 | 63 | |
| -0.74 | 1.29 | 1.86 | 1.73 | |
| 45.2% | 57.5% | 59.8% | 59.3% | |
| 7.2% | 29.5% | 26.4% | 22.9% | |
| -5.4% | 8.5% | 11.0% | 8.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,174 | 1,143 | 1,664 | 1,657 |
| Cash | 174 | 239 | 71 | 231 |
| Total debt | 709 | 674 | 859 | 815 |
| Total liabilities | 979 | 948 | 1,435 | 1,355 |
| 195 | 195 | 229 | 302 | |
| 34 | 42 | 40 | 40 | |
| 3.0% | 14.4% | 12.5% | 12.4% | |
| -12.8% | 24.6% | 30.2% | 20.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 124 | 275 | 205 | 329 | |
| 2 | 0 | 2 | 2 | |
| 123 | 274 | 203 | 328 | |
| Dividends paid | – | – | – | – |
| 14 | 75 | 60 | 25 | |
| 23 | 27 | 32 | 42 |
Valuation
- 12.5×
- 3.5×
- –
- 3.7×
- 1.0×
- 2.4×
- 3.4×
- 41.6%
- 8.0%
- 0.0%
Profitability
- 59.3%
- 22.9%
- 8.1%
- 76.3%
- 10.5%
- 5.9%
- 26.7%
- 4.5%
- 15.6%
- –
Growth
- +18.9%
- –
- +61.1%
- –
- −2.4%
Financial health
- 0.9×
- 2.59
- 48.9%
- 1.2×
- 1.71
- 1.62
- 0.48
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 26%of 946
Top 18%of 871
Top 14%of 563
Top 31%of 867
Top 1%of 986
What analysts expect
- Average price target
- $58.00
- Range
- $56.00 – $60.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 1.76 | 1.52 | +15.8% |
| Feb 26, 2026 | 2.04 | 2.14 | −4.7% |
| Nov 6, 2025 | 2.25 | 1.86 | +21.0% |
| Aug 7, 2025 | 1.68 | 1.62 | +3.7% |
| May 8, 2025 | 1.49 | 1.43 | +4.2% |
| Feb 27, 2025 | 1.77 | 1.54 | +14.9% |
| Nov 7, 2024 | 1.61 | 1.59 | +1.3% |
| Aug 8, 2024 | 1.62 | 1.49 | +8.7% |
News
Collegium Pharmaceutical, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
34No pass
Philip Fisher
70Pass
Peter Lynch
51No pass
Joel Greenblatt
51No pass
Charlie Munger
55No pass
Terry Smith
52No pass
Questions about Collegium Pharmaceutical
Is Collegium Pharmaceutical a good stock to buy?
A solid business, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Collegium Pharmaceutical AI analysis
What does Collegium Pharmaceutical do?
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. It is in Drug Manufacturers - Specialty & Generic.
Does Collegium Pharmaceutical pay a dividend?
No. Collegium Pharmaceutical does not pay a dividend at the moment; in 2025 it returned $25.1 million to shareholders by buying back its own shares.
Is Collegium Pharmaceutical stock halal?
No. Collegium Pharmaceutical does not pass our halal screen: its debt is 104% of its market value, at or above the 33% limit. How we check
How has Collegium Pharmaceutical stock done over the past year?
Down 45.4% over the past twelve months, to $25.32. It traded between $21.53 and $49.84 and is 49.2% below its high.
Who are Collegium Pharmaceutical's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Collegium Pharmaceutical's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.